Savolitinib Wins Breakthrough Therapy Designation in China for Gastric Cancer With MET Amplification
The Center for Drug Evaluation, of the National Medical Products Administration in China, has granted a breakthrough therapy designation to savolitinib for use in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction with MET amplification in whom at least 2 lines of standard therapy have failed.
National Medical Products Administration Drug Evaluation Gastric Cancer Gastroesophageal Junction Adenocarcinoma Met Amplification Breakthrough Designation
Source: onclive.com